Deferred income tax benefit was $94.8 million during the three months ended September 30, 2021, due to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Omniome and Circulomics acquisitions. Pacific Biosciences of California, Inc. Unaudited Condensed Consolidated Balance Sheets (in thousands) Pacific Biosciences of California, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands, except per share amounts)  (1) Merger-related expenses consisted of transaction costs arising from the acquisitions of Omniome and Circulomics and stock-based compensation expense resulting from the acceleration of certain equity awards in connection with the Omniome merger. (2) A deferred income tax expense (benefit) was related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Omniome and Circulomics acquisitions.